6月30日，Abivax S.A.夜盘上涨27.93%，报123.0美元/股，成交额1230.0美元。
消息面上，公司公布ABTECT维持试验Part 2积极数据：50mg obefazimod在诱导期未应答患者中实现37.2%临床缓解率及61.5%临床应答率；维持期复发患者重新用药后应答率和缓解率分别达69.7%和45.0%，且未出现新安全信号。此前50mg组曾报告多例癌症病例致股价一度暴跌近50%，本次补充数据安全性无新增隐患，争议逐步消化叠加疗效确认，多头情绪加速升温，股价持续回补前期跌幅。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.